Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading

Latest News

Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
defenseworld.net

Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP

Alpha Wave Global LP increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,312 shares of the company's stock after acquiring an additional 51,470 shares during the period. Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Q4 Earnings Call Highlights
defenseworld.net

Amylyx Pharmaceuticals Q4 Earnings Call Highlights

Amylyx Pharmaceuticals (NASDAQ: AMLX) executives told investors the company entered 2026 with a focus on advancing avexitide toward what could become the first FDA-approved therapy for post-bariatric hypoglycemia (PBH), while continuing early-stage work across its pipeline and maintaining a cash runway management said extends into 2028. Avexitide's pivotal trial: timeline, endpoint, and powering assumptions Co-CEO Justin

Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
seekingalpha.com

Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagonist in phase 3 LUCIDITY for post-bariatric hypoglycemia, with topline data expected Q3 2026. The company maintains a strong cash position [$317M, funding into 2028], supporting key milestones including potential avexitide commercialization.

Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout
defenseworld.net

Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout

Amylyx Pharmaceuticals (NASDAQ: AMLX) executives outlined a slate of milestones they expect to shape the company's near-term trajectory during TD Cowen's 46th Annual Healthcare Conference, with co-CEOs Josh Cohen and Justin Klee emphasizing that 2026 could be "transformative" primarily due to a pivotal readout for avexitide in post-bariatric hypoglycemia (PBH). Avexitide Phase 3 timeline and near-term

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av.

Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
defenseworld.net

Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Theravance Biopharma and

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
businesswire.com

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very.

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
businesswire.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
businesswire.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). If you currently own shares of Amylyx Pharmaceuticals stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=22470 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenleg.